Answers are grounded in this paper and cite their sources.
Most frameshift mutations that disrupt the activity of the transcription factor CRX exert a dominant-negative effect and are associated with elevated mRNA and protein levels. Here, we identified a subset of mutations that increase protein abundance without altering transcript levels, likely due to the loss of endogenous degradation signals and/or higher protein stability. We further demonstrate that CRX can be post-translationally regulated by ubiquitination, which controls its protein abundance via the proteasome. Based on this mechanism, we developed camelid ubiquibodies targeting novel CRX epitopes generated by frameshift variants to promote selective protein degradation. Notably, approximately two-thirds of pathogenic CRX variants are frameshift mutations, and several share common C-terminal epitopes, enabling a single targeting approach. As a proof-of-concept, we used the truncated protein encoded by the p.G122Afs*65 pathogenic variant to screen CRX-specific nanobodies and engineer them into ubiquibodies. We show that these mutant CRX proteins can be degraded more effectively than wild type by at least three different ubiquibodies via the proteasome. Together, these results establish protein degradation as a promising approach to eliminate frameshift-derived neoepitopes in dominant inherited retinal dystrophies and potentially other genetic disorders. In addition, this work provides new insights into the physiological regulation of CRX and contributes to a better understanding of the pathogenic mechanisms underlying its variants and associated clinical phenotypes.
No takes yet. Share an insight, caveat, or question.
Gómez-Escribano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: